Recently, Shen et al. reported that Rg1 released in brain tissue using nano-drug delivery systems reduced the volume of cerebral infarction and improved neural recovery in diabetic rats with cerebral infarction [59], indicating that the hypoglycemic effect of Rg1 may be regulated through the central nervous system. The gene discussed is PPP1R3A; the disease is cerebral infarction.